July 22, 2019 10:10 AM EDTUpdated July 24, 11:03 AM
R&D
FDA+

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

John Carroll

Editor & Founder

The non­prof­it Bioethics In­ter­na­tion­al has come out with their lat­est score­card on da­ta trans­paren­cy among the big bio­phar­mas in the in­dus­try — flag­ging

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta halts Duchenne gene ther­a­py in some pa­tients af­ter sec­ond death

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

A service from the Financial Times